Schröder S, Schwarz W, Rehpenning W, Löning T, Böcker W
Institute of Pathology, University of Hamburg, Federal Republic of Germany.
Virchows Arch A Pathol Anat Histopathol. 1987;411(5):435-9. doi: 10.1007/BF00735224.
Leu-M1 antigen is a monocyte/granulocyte-related marker known to be consistently expressed in the Reed-Sternberg cells of patients with Hodgkin's disease. Recently, however, the presence of Leu-M1 has also been noted in tumour cells of a variety of non-haematopoietic neoplasms, most of them adenocarcinomas. The biological significance of this aberrant reaction has not been clarified. We have been able to demonstrate marked epithelial Leu-M1 immunoreactivity (greater than 15% tumour cells positively stained) in 24 out of 76 (32%) papillary carcinomas of the thyroid gland (PC). This phenomenon was more frequently observed among PCs at an advanced stage of disease (pT4 vs. pT1-3 and M1 vs M0 p less than 0.05). The degree of epithelial Leu-M1 positivity was also shown to be significantly correlated to the clinical course of PC. Irrespective of other morphological and clinical features, death resulting from cancer occurred 17 times more frequently among PCs with marked Leu-M1 positivity (8/24) when compared with tumours with only slight or absent immunoreactivity (1/52) (p less than 0.00005). These findings suggest that Leu-M1 immunostaining provides significant prognostic information for patients with papillary carcinoma of the thyroid gland.
Leu-M1抗原是一种与单核细胞/粒细胞相关的标志物，已知在霍奇金病患者的里德-施特恩伯格细胞中持续表达。然而，最近在多种非造血性肿瘤的肿瘤细胞中也发现了Leu-M1的存在，其中大多数为腺癌。这种异常反应的生物学意义尚未阐明。我们发现，在76例甲状腺乳头状癌（PC）中，有24例（32%）显示出明显的上皮Leu-M1免疫反应性（超过15%的肿瘤细胞呈阳性染色）。在疾病晚期的PC中更常观察到这种现象（pT4与pT1-3相比，M1与M0相比，p<0.05）。上皮Leu-M1阳性程度也与PC的临床病程显著相关。无论其他形态学和临床特征如何，与Leu-M1阳性程度轻微或无免疫反应的肿瘤（1/52）相比，Leu-M1阳性明显的PC患者因癌症死亡的频率高17倍（8/24）（p<0.00005）。这些发现表明，Leu-M1免疫染色可为甲状腺乳头状癌患者提供重要的预后信息。
